SAN.PA - Sanofi

Paris - Paris Delayed Price. Currency in EUR
83.81
-0.45 (-0.53%)
At close: 5:37PM CEST
Stock chart is not supported by your current browser
Previous Close84.26
Open84.32
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range83.81 - 84.55
52 Week Range24.55 - 87.65
Volume2,205,530
Avg. Volume20,062
Market Cap103.12B
Beta0.73
PE Ratio (TTM)11.69
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.30 (3.40%)
Ex-Dividend Date2017-05-16
1y Target EstN/A
  • Reuters3 days ago

    Regeneron-Sanofi drug succeeds mid-stage study

    The drug, dupilumab, was statistically significant in improving the ability to swallow in adults with moderate-to-severe eosinophilic esophagitis, when compared with a placebo. Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the pipe that connects the throat and the stomach, and can lead to food getting stuck in the oesophagus and difficulties in swallowing.

  • Sanofi/Regeneron's Dupixent Succeeds in Phase II Study
    Zacks3 days ago

    Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

    Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.

  • Market Realist3 days ago

    Sanofi’s Consumer Healthcare Expected to Be Long-Term Driver

    In 2Q17, Sanofi’s (SNY) Consumer Healthcare business reported revenues of 1.2 billion euros, which is a 42.5% YoY rise on a CER basis and a YoY fall of 0.10% on a CER and CS basis.

  • Reuters4 days ago

    UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study

    Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study. The drug, dupilumab, was statistically significant in improving the ability to swallow in adults with moderate-to-severe eosinophilic esophagitis, when compared with a placebo. Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the pipe that connects the throat and the stomach, and can lead to food getting stuck in the esophagus and difficulties in swallowing.

  • Market Realist4 days ago

    Vaccines Business Expected to Boost Sanofi’s Revenues in 2017

    In 2Q17, Sanofi’s (SNY) vaccine business reported revenues of 1.0 billion euros, which is a YoY rise of 26.2% on a CER basis and 19.2% on a CER and CS basis.

  • Reuters4 days ago

    Aimmune teams with Regeneron, Sanofi on peanut allergy drug

    Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug. The company said it would test the drug, AR101, in combination with Regeneron and Sanofi's dupilumab in a mid-stage trial that is expected to start in 2018 and will be sponsored by Regeneron. AR101, an oral immunotherapy, is already being tested as a mono-therapy for peanut allergy in a late-stage trial.

  • Market Realist4 days ago

    Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis

    Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.

  • Reuters4 days ago

    Regeneron-Sanofi throat infection drug succeeds key study

    Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat patients with a rare throat infection met the main goal of a mid-stage study. The drug, dupilumab, was statistically significant ...

  • Regeneron Advances Science To Attack Arthritis, Eye Disease, More
    Investor's Business Daily4 days ago

    Regeneron Advances Science To Attack Arthritis, Eye Disease, More

    Regeneron became a star with its treatment for a common eye disease, but treatments for dermatitis, arthritis, asthma and cancer could bring superstardom.

  • Market Realist4 days ago

    Dupixent May Be Strong Growth Driver for Sanofi in the Future

    Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).

  • The Wall Street Journal4 days ago

    [$$] Warp Drive Bio, Roche Forge $387 Million Antibiotics Pact

    Warp Drive Bio Inc. could wind up $387 million richer thanks to a new antibiotic drug deal struck with Roche.

  • Market Realist7 days ago

    Specialty Segment Drives Sanofi’s Revenue Growth in 2017

    In 2Q17, Sanofi’s (SNY) Sanofi Genzyme, its specialty care business, reported revenues of 1.7 billion euros, which is a 13.6% rise YoY (year-over-year).

  • Market Realist7 days ago

    Sanofi and Its Peers: Analysts’ Recommendations in October

    Of the three analysts covering Sanofi in October 2017, two have rated the stock a “strong buy,” and one has rated it a “hold.”

  • Forbes7 days ago

    Big Pharma Killed The Cancer Drug He Invented. He Raised $22 Million To Revive It

    “They were asking for help to get the drug back. They were dying. Most of them died. It was very motivating to try to get it back."

  • Motley Fool8 days ago

    A New FDA Approval Sends Small Cap Flexion Soaring

    Flexion's non-opioid pain management drug has huge potential, and it's looking to expand into more indications.

  • Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
    Zacks9 days ago

    Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

    With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

  • This Biotech Hit Record High; Could Undercut Regeneron In Eczema
    Investor's Business Daily10 days ago

    This Biotech Hit Record High; Could Undercut Regeneron In Eczema

    AnaptysBio soared Tuesday after its eczema drug appeared to outperform a potential blockbuster rival drug from Regeneron and Sanofi.

  • Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit
    Zacks11 days ago

    Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit

    Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.

  • 3 High-Yield Healthcare Stocks
    Motley Fool12 days ago

    3 High-Yield Healthcare Stocks

    If you're on the hunt for above-average yields, these three healthcare stocks should be on your radar.

  • Why Regeneron's Patent Win Is Worse For Amgen Than You Think
    Investor's Business Daily14 days ago

    Why Regeneron's Patent Win Is Worse For Amgen Than You Think

    Amgen's patents covering LDL cholesterol-lowering drug Repatha are likely to be invalidated, an analyst says.

  • Regeneron and Sanofi Get Favorable Ruling Against Amgen
    Zacks14 days ago

    Regeneron and Sanofi Get Favorable Ruling Against Amgen

    Regeneron Pharmaceuticals(REGN) and partner Sanofi, Inc. (SNY) receives a favorable ruling from the Court of Appeals for the Federal Circuit relating to Praluent.

  • At least six funds interested in Sanofi European generic drugs unit - Le Figaro
    Reuters15 days ago

    At least six funds interested in Sanofi European generic drugs unit - Le Figaro

    French pharmaceutical group Sanofi (SASY.PA) is set to start the process to sell its generic drug business in Europe, and at least six funds have expressed interest to investment banks mandated by group, France's Le Figaro newspaper reported. Rothschild and JP Morgan, two investment banks mandated by Sanofi to handle the divestment, will send out memos to potential buyers in the next few weeks, Le Figaro said in its Friday edition. Sources told Reuters in March that Rothschild [ROT.UL], JP Morgan (JPM.N) and Morgan Stanley (MS.N) had been asked to organise the long-awaited deal.

  • Reuters15 days ago

    At least six funds interested in Sanofi European generic drugs unit -Le Figaro

    French pharmaceutical group Sanofi is set to start the process to sell its generic drug business in Europe, and at least six funds have expressed interest to investment banks mandated by group, France's Le Figaro newspaper reported. Rothschild and JP Morgan, two investment banks mandated by Sanofi to handle the divestment, will send out memos to potential buyers in the next few weeks, Le Figaro said in its Friday edition. Sources told Reuters in March that Rothschild, JP Morgan and Morgan Stanley had been asked to organise the long-awaited deal.

  • The Wall Street Journal15 days ago

    [$$] Appeals Court Rules Against Amgen in Patent Case

    A U.S. federal appeals court said Regeneron Pharmaceuticals and partner Sanofi can continue selling their cholesterol drug, dealing a blow to rival Amgen, which had accused the companies of violating its ...

  • Reuters15 days ago

    U.S. court reverses ban on sale of Regeneron, Sanofi cholesterol drug

    A U.S. appeals court on Thursday threw out a ban on the sale of Regeneron Pharmaceuticals Inc and Sanofi SA's cholesterol-lowering drug Praluent, and ordered a new trial after finding a jury was given improper instructions. The ruling from the U.S. Court of Appeals for the Federal Circuit in Washington was a setback for Amgen Inc, which claimed Praluent infringed patents on its rival drug, Repatha, and had won the sales ban after a jury trial.